Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.

Antimicrobial agents and chemotherapy - 1 Apr 2011

Larrouy Lucile, Lambert-Niclot Sidonie, Charpentier Charlotte, Fourati Slim, Visseaux Benoit, Soulié Cathia, Wirden Marc, Katlama Christine, Yeni Patrick, Brun-Vézinet Françoise, Calvez Vincent, Marcelin Anne-Geneviève, Descamps Diane

Abstract excerpt

We assessed the roles of baseline gag and gag-pol cleavage site mutations (CSM) on the virological outcome of a darunavir-based regimen in highly antiretroviral-experienced patients. We showed the association, in multivariate analysis, between the A431V gag CSM and the virological response, defined as a reduction in plasma HIV-1 RNA to <50 copies/ml at month 3 (P = 0.028). Our results suggest that a specific gag...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Mutation

Share to Ritonavir

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 21282435
DOI: 10.1128/AAC.01049-10
PMCID: PMC3067137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.PMID 21282435Read ↗

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.Semantic proximity Read ↗

Mutations in HIV-1 gag cleavage sites and their association with protease mutations.Semantic proximity Read ↗

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.Semantic proximity Read ↗

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.Semantic proximity Read ↗

Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Semantic proximity Read ↗

Role of Gag in HIV Resistance to Protease InhibitorsSemantic proximity Read ↗

Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.Semantic proximity Read ↗

Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease InhibitorsSemantic proximity Read ↗

Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.Semantic proximity Read ↗

Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.Semantic proximity Read ↗

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.